The results demonstrate that STAT1-CC has strong anti-tumor effects in lung cancer cells in response to IFNs and indicate that combined treatment of IFNs and STAT1-CC could be of potential value for further research in vivo and in an eventual therapeutic approach for treatment of human lung cancer. The gene discussed is STAT1; the disease is lung cancer.